From: Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure
DTG | RAL | EFV | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
95% | 95% | 95% | ||||||||
IC50 | confidence | IC50 | confidence | IC50 | confidence | |||||
Backbone | Genotype | (nM) | intervals(nM) | FC | (nM) | intervals(nM) | FC | (nM) | intervals(nM) | FC |
pNL4-3 | WT | 6.897 | 5.714 to 8.324 | - | 11.51 | 9.833 to 13.46 | - | 1.352 | 0.964 to 1.897 | - |
H51Y | 9.278 | 7.707 to 11.17 | 1.3 | 13.42 | 11.62 to 15.50 | 1.2 | 1.373 | 0.957 to 1.970 | 1 | |
R263K | 73.36 | 29.91 to 180 | 10.6 | 12.44 | 10.06 to 15.38 | 1.1 | 1.143 | 0.763 to 1.712 | 0.8 | |
H51Y/R263K | 113.8 | 77.43 to 167.2 | 16.5 | 24.28 | 15.51 to 38.00 | 2.1 | 1.212 | 0.852 to 1.723 | 0.9 |